These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16290998)

  • 1. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation.
    Dernellis J; Panaretou M
    Am Heart J; 2005 Nov; 150(5):1064. PubMed ID: 16290998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
    Patti G; Chello M; Candura D; Pasceri V; D'Ambrosio A; Covino E; Di Sciascio G
    Circulation; 2006 Oct; 114(14):1455-61. PubMed ID: 17000910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation.
    Dernellis J; Panaretou M
    Eur Heart J; 2004 Jul; 25(13):1100-7. PubMed ID: 15231367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion.
    Ozaydin M; Varol E; Aslan SM; Kucuktepe Z; Dogan A; Ozturk M; Altinbas A
    Am J Cardiol; 2006 May; 97(10):1490-3. PubMed ID: 16679090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.
    Zhou T; Zhou SH; Qi SS; Shen XQ; Zeng GF; Zhou HN
    Clin Chim Acta; 2006 Jun; 368(1-2):168-72. PubMed ID: 16480969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery.
    Song YB; On YK; Kim JH; Shin DH; Kim JS; Sung J; Lee SH; Kim WS; Lee YT
    Am Heart J; 2008 Aug; 156(2):373.e9-16. PubMed ID: 18657672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
    Kumagai K; Nakashima H; Saku K
    Cardiovasc Res; 2004 Apr; 62(1):105-11. PubMed ID: 15023557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study.
    Almroth H; Höglund N; Boman K; Englund A; Jensen S; Kjellman B; Tornvall P; Rosenqvist M
    Eur Heart J; 2009 Apr; 30(7):827-33. PubMed ID: 19202157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation.
    Hatzinikolaou-Kotsakou E; Tziakas D; Hotidis A; Stakos D; Floros D; Papanas N; Chalikias G; Maltezos E; Hatseras DI
    Am J Cardiol; 2006 Mar; 97(5):659-61. PubMed ID: 16490433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease.
    Aguilar EM; Miralles Jde H; González AF; Casariego CV; Moreno SB; García FA
    Eur J Vasc Endovasc Surg; 2009 Apr; 37(4):443-7. PubMed ID: 19211277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
    Boonbaichaiyapruck S; Cheepudomwit S; Panjavenin P; Suthichaiyakul T; Moleelerkpoom W; Benjanuwatra T; Sukanandachai B; Buakhamsri A
    J Med Assoc Thai; 2008 Aug; 91(8):1189-95. PubMed ID: 18788689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population.
    Marott SC; Nordestgaard BG; Zacho J; Friberg J; Jensen GB; Tybjaerg-Hansen A; Benn M
    J Am Coll Cardiol; 2010 Aug; 56(10):789-95. PubMed ID: 20797493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
    Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
    Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial.
    Tsai CT; Lai LP; Hwang JJ; Wang YC; Chiang FT; Lin JL
    Am Heart J; 2008 Jul; 156(1):65-70. PubMed ID: 18585498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation.
    Buob A; Jung J; Siaplaouras S; Neuberger HR; Mewis C
    Pacing Clin Electrophysiol; 2006 Jun; 29(6):559-63. PubMed ID: 16784419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.